Lilly bolts another one on, acquiring Point Biopharma for $1.4 billion

A couple billion here, a couple billion there, and pretty soon Eli Lilly hopes it will be talking about real money.

Eli Lilly agreed to purchase Point Biopharma Tuesday morning for $1.4 billion, a 90% premium, adding to its pipeline of cancer drugs. Point is developing cancer drugs that deliver a focused dose of radiation to tumor cells. Data for its lead medicine, for prostate cancer, are expected in the fourth quarter. It is also developing a drug for neuroendocrine tumors.

Point operates a 180,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, and a radiopharmaceutical research and development center in Toronto.

Get unlimited access to award-winning journalism and exclusive events.

You Think the TREE Is Crooked: Penile Fractures Up at Christmas

Talk about taking a break for the holidays: A new German study found that penile fractures are more likely to occur around Christmas Day. From

December 23, 2023

CTX-130 by CRISPR Therapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 26, 2023

New trial of a preventive HIV vaccine candidate begins in the United States and South Africa

A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa.

September 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.